Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
- Notice of Effectiveness (EFFECT)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
NOTICE OF EFFECTIVENESS
Effective Date: February 03, 2011
Form: S-1
CIK: 0000897075
Company Name: REPROS THERAPEUTICS INC.
File Number: 333-171196
dkam is on a run oh look out here we go
let her go and run and fly$$$$$$
alot of work vpro has to be in this somehow Global Bladder Cancer Therapeutics Industry
Posted on: Wed, 02 Feb 2011 07:09:00 EST
Symbols: CTHP
NEW YORK, Feb. 2, 2011 /PRNewswire via COMTEX/ --
Reportlinker.com announces that a new market research report is available in its catalogue:
Global Bladder Cancer Therapeutics Industry
http://www.reportlinker.com/p0181075/Global-Bladder-Cancer-Therapeutics-Industry.html
This report analyzes the worldwide markets for Bladder Cancer Therapeutics in US$ Million. The report provides separate comprehensive analytics for US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. A six-year historic analysis is also provided for these markets. The report profiles 62 companies including many key and niche players such as Affitech A/S, Allergan, Inc., Allos Therapeutics, Inc., Astellas Pharma, Inc., Astrazeneca Plc, AVI BioPharma, Inc., BioCancell Therapeutics, Inc., Bioniche Life Sciences, Inc., Bristol-Myers Squibb Company, Celldex Therapeutics, Inc., Cytavis BioPharma GMBH, Eli Lilly and Company, Endo Pharmaceuticals Holdings, Inc., ENKAM Pharmaceuticals A/S, F. Hoffmann-La Roche Ltd., Halozyme Therapeutics, Inc., Laboratoires Pierre Fabre SA, NatImmune A/S, Oncogenex Pharmaceuticals, Inc., OncoTherapy Science, Inc., Sanofi-Aventis, Spectrum Pharmaceuticals, Inc., Telormedix SA, and Viventia Biotechnologies, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
BLADDER CANCER THERAPEUTICS MCP-6020
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-3
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW II-1
Introduction II-1
Bladder Cancer Growing at an Alarming Rate II-1
Bladder Cancer Statistics II-1
Table 1: Worldwide Incidence of Bladder Cancer by Select
Countries/Region (2003 & 2013): US, Europe, and Japan (In
'000s) (includes corresponding Graph/Chart) II-1
Table 2: Worldwide Incidence and Mortality Rates of Select
Cancer Types in Males: 2007 (includes corresponding
Graph/Chart) II-2
Table 3: Incidence and Mortality Rates of Select Cancer Types
in Industrialized Countries: 2007 (includes corresponding
Graph/Chart) II-3
Table 4: Incidence and Mortality Rates of Select Cancer Types
in Developing Markets: 2007 (includes corresponding
Graph/Chart) II-4
Recurrent Nature: A Major Cause of Concern II-4
Bladder Cancer: The Most Costly Cancer To Treat II-5
Generics Characterize Bladder Cancer Market II-5
Existing Drug Therapies Lack in Assuring Long Term Survival Rate II-5
Approved Intravesical Agents for Bladder Cancer II-6
Bladder Cancer Demands New Therapeutics to Fill the Void II-6
Table 5: Number of Pipeline Drugs by Select Cancer Types
(includes corresponding Graph/Chart) II-7
What the Future Holds? II-7
Table 6: World Market for Bladder Cancer Therapeutics (2008):
Percentage Share Breakdown of Total Number of Drugs by
Development Stage (includes corresponding Graph/Chart) II-7
Emerging Therapeutic Options for Superficial Bladder Cancer II-8
Table 7: EOquin Penetration Rate in the US for the Years
2011 through 2015 (includes corresponding Graph/Chart) II-8
Table 8: US Market for EOquin: Annual Revenue Projections
for the Years 2011 through 2015 in US$ Million (includes
corresponding Graph/Chart) II-9
Registration Process for New Drugs: A Review II-9
Competitive Landscape II-9
Leading Therapeutics in Global Bladder Cancer Market II-10
Select Companies Involved in Late-Stage Bladder Cancer
Clinical Trials II-10
Select Companies Involved in Phase-II Clinical Trials II-11
Select Companies Involved in Phase-I Clinical Trials II-11
Select Companies Involved in Pre-clinical Stage II-11
Current and Future Analysis II-12
2. MAJOR TRENDS & ISSUES II-13
Cigarette Smoking and Carcinogenic Substances: The Major Culprits II-13
Men at High Risk than Women II-13
New Therapeutics for Elderly Population: Need of the Hour II-13
Lasers for Bladder Cancer Treatment: An Evolving Approach II-14
Photodynamic Therapy (PDT) Holds Potential II-14
SonoPhoto Dynamic Therapy - A New Treatment for Non-Invasive
Bladder Cancer II-14
3. BLADDER CANCER TREATMENT II-15
Non-Invasive (Superficial) Bladder Cancer Treatment II-15
Treatment Options and Potential Side Effects II-15
Surgery II-15
Immunotherapy II-16
Intravesical Chemotherapy II-16
Invasive Bladder Cancer Treatment II-17
Treatment Options, and Potential Side Effects II-17
Surgery II-17
Cystectomy II-17
Partial Cystectomy - A Part of Bladder is Removed II-17
Radical Cystectomy - Entire Bladder is Removed II-18
Side Effects of Removing the Bladder II-18
What's the Solution if the Bladder Is Removed? II-18
Reconstructive Surgery II-18
Continent Urinary Diversion or Ileal Loop Diversion II-18
Neobladder II-19
Radiotherapy II-19
Systemic Chemotherapy II-20
Metastatic Bladder Cancer II-20
Palliative Treatment II-20
Other Treatment Options II-21
Targeted Therapy II-21
Gene Therapy II-21
Chemoprevention II-21
Chemoradiotherapy II-21
Photodynamic Therapy (PDT) II-21
Complementary Therapies II-21
4. MAJOR BLADDER CANCER DRUGS II-22
A Quick Market Primer II-22
Leading Bladder Cancer Therapeutics II-22
Select Bladder Cancer Therapeutics in Pipeline: 2009 II-23
Approved Bladder Cancer Drugs II-24
Thiotepa II-24
Adriamycin (Doxorubican hydrochloride) II-24
Methotrexate II-24
Vinblastine II-24
Epirubicin II-24
Mitomycin C II-25
Mitoxzantrone II-25
Oxaliplatin II-25
IL2 (Aldesleukin) and Interferon into the Bladder II-25
Keyhole Limpet Haemocyanin (KLH) II-25
Platinol-AQ (Cisplatin) II-25
Gemzar (Gemcitabine) II-26
OncoTICE/TICE BCG II-26
PACIS(TM) BCG II-26
Valstar (valrubicin) II-26
Late-Stage Pipeline Drugs II-27
EOquin (Apaziquone) II-27
Urocidin (MCC) II-28
Larotaxel (XRP-9881) II-28
Javlor(R) (Vinflunine) II-28
4-HPR (Fenretinide) II-29
Pipeline Analysis of Other Potential Drugs II-29
BEXIDEM [On-Hold] II-29
BC-819 [Phase IIb] II-29
CDX-1307 [Phase I] II-30
Chemophase(R) [Phase I/IIa] II-30
PDX [Pralatrexate] [Phase II] II-30
OGX-427 [Phase I] II-30
OGX-011 [Phase II] II-30
Celebrex (Celecoxib) [Phase IIb/III] II-31
TMX-101 [Pre-Clinical Stage] II-31
AGSPSCA [Phase Ib] II-31
Iressa with Gemzar [Phase II] II-31
MDR09521[Development Stage] II-32
siRNA ALPHAGEN [Development Stage] II-32
5. AN OVERVIEW OF BLADDER CANCER II-33
Cancer - An Insight II-33
Factors Causing Cancer Ranked in Order of Impact II-33
Cancer Diagnosis II-34
Treatment Strategies for Cancer II-34
Progressing R&D Efforts to Innovate Drug Delivery for Cancer
Treatment II-34
The Human Bladder: A Urine Storing Organ II-35
Bladder Cancer - Introduction II-35
Classification of Bladder Cancer II-35
Non-Invasive Cancer II-35
Invasive Cancer II-35
Types of Bladder Cancer II-36
Transitional Cell Carcinoma/Urothelial Carcinoma II-36
Squamous Cell Carcinoma II-36
Adenocarcinoma II-36
Table 9: US Prevalence of Bladder Cancer by Type (includes
corresponding Graph/Chart) II-36
Major Risk Factors II-37
Controllable Risk Factors II-37
Uncontrollable Risk Factors II-37
Symptoms and Diagnosis II-38
Symptoms II-38
Diagnosis II-38
General Diagnostic Tests II-39
Blood Tests II-39
Physical Examination II-39
Urine Test II-39
Prescribed Procedure to Locate Bladder Cancer II-39
Cytoscopy and Biopsy II-39
Intravenous Pyelogram (IVP) II-39
Ultrasound Scanning II-39
Test/Procedures to Confirm Cancer Penetration II-40
CT Scan II-40
Radioisotope Bone Scan II-40
Staging and Grading of Bladder Cancer: Crucial for Treatment II-40
Staging II-40
Grading II-41
6. RESEARCH & DEVELOPMENT II-42
Variations in PSCA Gene Increase Risk of Bladder Cancer II-42
Genetic Analysis for Assaying Bladder Cancer Recurrence II-42
Selenium Allays the Risk of Bladder Cancer II-43
Individuals with Common Genome Variants at Increased Risk of
Developing Bladder Cancer II-43
New Studies Reveal Correlation Between Coffee and Bladder Cancer II-43
Raw Cruciferous Vegetables Alleviates the Risk of Bladder Cancer II-44
Broccoli Sprouts a Super-Food to Prevent Bladder Cancer II-44
Well Water Counts to the Risk Factors for the Bladder cancer II-44
Frankincense Oil: Potentially a Future Aid for Bladder Cancer II-44
SRC Gene Suppresses Bladder Cancer Metastases II-45
7. FDA APPROVALS AND FILINGS II-46
Allos Therapeutics Obtains FDA Orphan Drug Designation for
Pralatrexate II-46
Aeterna Zentaris Secures FDA Approval for IND Application of
AEZS-108 II-46
Biocancell Obtains FDA Clearance to Continue Clinical Trial
for BC-819 II-46
Bioniche to Commence Additional Phase III Clinical Trial of
Urocidin(TM) II-46
Bioniche Obtains FDA Approval for Phase III Trial of Urocidin II-47
FDA Grants Fast Track Designation for Apaziquone (EOquin(R)) II-47
Indevus Receives FDA Nod for Valstar II-48
Biocancell Obtains FDA Approval of BC-819 for Phase IIb
Clinical Trail II-48
8. RECENT INDUSTRY ACTIVITY II-49
MDRNA Takes Over Cequent Pharmaceuticals II-49
MDRNA Changes Name to Marina Biotech II-49
Telormedix Commences Phase I/II clinical Trial for TMX-101 II-49
Spectrum and Handok Ink Joint Marketing Agreement for
Apaziquone in Korea II-50
MDRNA Expands and Extends Collaboration with VPC II-50
Endo Pharmaceuticals Acquires Indevus Pharmaceuticals II-50
Affitech Merges with Pharmexa II-51
Takeda America Holdings Acquires IDM Pharma II-51
Schering-Plough Merges with Merck II-51
Cell Genesys Merges with BioSante Pharmaceuticals II-51
Celldex Therapeutics Acquires CuraGen II-51
EMEA Grants Orphan Medicinal Product Designation for Pralatrexate II-52
Endo Pharmaceuticals Obtains License for Urocidin II-52
CHMP Issues Positive Opinion on JAVLOR(R) to Treat Metastatic
Bladder Cancer II-52
BioCis Pharma Initiates Phase I Clinical Trial of ProtoCure(TM) II-53
Sonus Pharmaceuticals Acquires OncoGenex Technologies II-53
Callisto Merges with Celldex Therapeutics II-53
Allergan and Spectrum Pharmaceuticals Collaborate for Apaziquone II-53
Pro-Pharmaceuticals and BioCancell Collaborate to Administer
siRNA for H19 Genes Destruction in Cancerous Cells II-54
AVANT Adopts New Identity as Celldex Therapeutics II-54
Lorus Therapeutics Receives New Patent for LOR-2040, Leukemia
Drug II-55
Spectrum Pharmaceuticals Obtains Canadian Authorities Approval
for Phase III Clinical Trial of EOquin II-55
NCCN Obtains Grant to Evaluate Cetuximab Efficacy in Bladder
Cancer II-55
Allos Therapeutics Commences Phase II Trials for Pralatrexate II-56
Halozyme Announces Status Update of Chemophase(R) Phase I/IIa
Clinical Trial II-56
Spectrum Pharmaceuticals Establishes New Company in Canada II-56
China Medical Technologies Acquires FISH Business II-56
Peregrine Acquires Global License for Anti-Angiogenesis
Technology II-57
Bristol-Myers Terminates Partnership with Pierre Fabre II-57
9. FOCUS ON SELECT GLOBAL PLAYERS II-58
Affitech A/S (Denmark) II-58
Allergan, Inc. (USA) II-58
Allos Therapeutics, Inc. (USA) II-59
Astellas Pharma, Inc. (Japan) II-59
Astrazeneca Plc. (UK) II-59
AVI BioPharma, Inc. (USA) II-60
BioCancell Therapeutics, Inc. (Israel) II-60
Bioniche Life Sciences, Inc. (Canada) II-61
Bristol-Myers Squibb Company (USA) II-61
Celldex Therapeutics, Inc. (USA) II-62
Cytavis BioPharma GmbH (Germany) II-62
Eli Lilly and Company (USA) II-63
Endo Pharmaceuticals Holdings, Inc. (USA) II-63
ENKAM Pharmaceuticals A/S (Denmark) II-64
F. Hoffmann-La Roche Ltd. (Switzerland) II-64
Halozyme Therapeutics, Inc. (USA) II-64
Laboratoires Pierre Fabre SA (France) II-65
NatImmune A/S (Denmark) II-65
Oncogenex Pharmaceuticals, Inc. (USA) II-66
OncoTherapy Science, Inc. (Japan) II-66
Sanofi-Aventis (France) II-66
Spectrum Pharmaceuticals, Inc. (USA) II-67
Telormedix SA (Switzerland) II-67
Viventia Biotechnologies, Inc. (Canada) II-68
10. GLOBAL MARKET PERSPECTIVE II-69
Table 10: World Recent Past, Current & Future Analysis for
Bladder Cancer Therapeutics by Geographic Region - US, Japan,
Europe, and Rest of World Markets Independently Analyzed by
Annual Revenues in US$ Million for the Years 2007 through 2015
(includes corresponding Graph/Chart) II-69
Table 11: World Historic Review for Bladder Cancer
Therapeutics by Geographic Region - US, Japan, Europe, and
Rest of World Markets Independently Analyzed by Annual
Revenues in US$ Million for the Years 2001 through 2006
(includes corresponding Graph/Chart) II-70
Table 12: World 11-Year Perspective for Bladder Cancer
Therapeutics by Geographic Region - Percentage Breakdown of
Revenues for US, Japan, Europe, and Rest of World Markets for
the Years 2005, 2010 & 2015 (includes corresponding
Graph/Chart) II-71
III. MARKET
1. UNITED STATES III-1
A. Market Analysis III-1
Bladder Cancer & Prevalence - A Recapitulation of Facts III-1
Mortality Rates Higher in African Americans III-2
Table 13: Incidence of Bladder Cancer Among African
Americans (Males): Percentage Share Breakdown by Select
Cancer/Type or Site and Gender for the Year 2007 (includes
corresponding Graph/Chart) III-2
Bladder Cancer - A Costly Urologic Condition III-3
Table 14: Urologic Disease Costs in the US: 2006 (includes
corresponding Graph/Chart) III-3
US Bladder Cancer Statistics III-3
Table 15: Bladder Cancer Prevalence and Mortality in the US
by Gender: Percentage Share Breakdown for 2009 III-3
Table 16: Bladder Cancer Incidence in the US by Gender:
Percentage Share Breakdown for 2008 III-3
FDA Approval III-4
Strategic Corporate Developments III-6
Select Players III-12
Allergan, Inc. III-12
Allos Therapeutics, Inc. III-13
AVI BioPharma, Inc. III-13
Bristol-Myers Squibb Company III-14
Celldex Therapeutics, Inc. III-14
Eli Lilly and Company III-15
Endo Pharmaceuticals Holdings, Inc. III-15
Halozyme Therapeutics, Inc. III-16
Marina Biotech, Inc. III-16
Oncogenex Pharmaceuticals, Inc. III-17
Peplin, Inc. III-17
Polyphenon Pharma III-17
Spectrum Pharmaceuticals, Inc. III-18
B. Market Analytics III-18
Table 17: US Recent Past, Current and Future Analysis for
Bladder Cancer Therapeutics - Annual Revenues in US$ Million
for the Years 2007 through 2015 (includes corresponding
Graph/Chart) III-18
Table 18: US Historic Review for Bladder Cancer Therapeutics -
Annual Revenues in US$ Million for the Years 2001 through
2006 (includes corresponding Graph/Chart) III-19
2. JAPAN III-20
A.Market Analysis III-20
Current & Future Analysis III-20
Select Players III-20
alphaGEN, Co., Ltd III-20
Astellas Pharma, Inc. III-20
Nippon Kayaku Co., Ltd III-20
OncoTherapy Science, Inc. III-21
B.Market Analytics III-22
Table 19: Japanese Recent Past, Current and Future Analysis
for Bladder Cancer Therapeutics - Annual Revenues in US$
Million for the Years 2007 through 2015 (includes
corresponding Graph/Chart) III-22
Table 20: Japanese Historic Review for Bladder Cancer
Therapeutics - Annual Revenues in US$ Million for the Years
2001 through 2006 (includes corresponding Graph/Chart) III-22
3. EUROPE III-23
A.Market Analysis III-23
Current & Future Analysis III-23
Bladder Cancer - Prevalence III-23
Table 21: Bladder Cancer Incidence in Europe by Region
(2006) for Germany, Italy, Spain, France, The UK,
Scandinavia, and Benelux (includes corresponding
Graph/Chart) III-23
Table 22: Bladder Cancer Mortality in Europe by Region
(2006) for Germany, Italy, the UK, Spain, France, Benelux,
and Scandinavia (includes corresponding Graph/Chart) III-24
Europe Lacks R&D Innovation in Bladder Cancer Market III-24
Focus on Select Regional Market III-24
United Kingdom III-24
Bladder Cancer Prevalence - A Review III-24
Bladder Cancer Statistics in the UK III-25
Table 23: Incidence, Mortality, and Five-Year Survival
Rate of Bladder Cancer in UK by Gender: 2006 III-25
Table 24: Bladder Cancer Incidence by Region (2006) for
England, Wales, Scotland, and Northern Ireland (includes
corresponding Graph/Chart) III-25
Table 25: Age-Specific Incidence of Bladder Cancer by
Gender: 2006 (includes corresponding Graph/Chart) III-25
Table 26: Number of Bladder Cancer Deaths in the UK
(2007): Breakdown by Region - England, Wales, Scotland,
and Northern Ireland (includes corresponding Graph/Chart) III-26
Table 27: Age-Specific Bladder Cancer Mortality Rate in UK
Males: Breakdown by Age Group for 2007 (includes
corresponding Graph/Chart) III-26
Table 28: Age-Specific Bladder Cancer Mortality Rate in UK
Females: Breakdown by Age Group for 2007 (includes
corresponding Graph/Chart) III-26
Strategic Corporate Developments III-26
Select Players III-28
Affitech A/S (Denmark) III-28
Astrazeneca PLC (UK) III-28
BioCis Pharma Ltd (Finland) III-29
Cambridge Laboratories Ltd. (UK) III-29
curasan AG (Germany) III-29
Cytavis BioPharma GmbH (Germany) III-29
ENKAM Pharmaceuticals A/S (Denmark) III-30
F. Hoffmann-La Roche Ltd. (Switzerland) III-30
Laboratoires Pierre Fabre SA (France) III-30
NatImmune A/S (Denmark) III-31
Sanofi-Aventis (France) III-31
Telormedix SA (Switzerland) III-32
B.Market Analytics III-33
Table 29: European Recent Past, Current and Future Analysis
for Bladder Cancer Therapeutics - Annual Revenues in US$
Million for the Years 2007 through 2015 (includes
corresponding Graph/Chart) III-33
Table 30: European Historic Review for Bladder Cancer
Therapeutics - Annual Revenues in US$ Million for the Years
2001 through 2006 (includes corresponding Graph/Chart) III-33
4. REST OF WORLD III-34
A.Market Analysis III-34
Current & Future Analysis III-34
Select Markets III-34
Canada III-34
Bladder Cancer Treatment III-34
Bladder Cancer Statistics III-34
Table 31: Bladder Cancer New Cases in Canada: Percentage
Share Breakdown by Gender for 2009 III-34
Table 32: Bladder Cancer Mortality in Canada: Percentage
Share Breakdown by Gender for 2009 III-35
Table 33: New Cases of Cancer Among Canadian Females by
Type: Percentage Share Breakdown for 2009 (includes
corresponding Graph/Chart) III-35
Table 34: Cancer Mortality Among Canadian Females by
Cancer Type: Percentage Share Breakdown for 2009
(includes corresponding Graph/Chart) III-36
Table 35: New Cases of Cancer Among Canadian Males by
Type: Percentage Share Breakdown for 2009 (includes
corresponding Graph/Chart) III-36
Table 36: Cancer Mortality among Canadian Males by Cancer
Type: Percentage Share Breakdown for 2009 (includes
corresponding Graph/Chart) III-37
Asia-Pacific III-37
China III-37
India III-37
Australia III-37
Women at Increased Risk Over Men in Australia - A New
Finding III-37
Table 37: Number of Deaths Due to Bladder Cancer:
Breakdown by Age Group for the Year 2006 (includes
corresponding Graph/Chart) III-38
Table 38: Age-Standardized Mortality Rate Due to Bladder
Cancer in Australia: Breakdown by Age Group for the Year
2006 (includes corresponding Graph/Chart) III-38
Table 39: Number of Deaths Due to Bladder Cancer
(Males): Breakdown by Age Group for the Year 2006
(includes corresponding Graph/Chart) III-39
Table 40: Number of Deaths Due to Bladder Cancer
(Females): Breakdown by Age Group for the Year 2006
(includes corresponding Graph/Chart) III-39
South Africa - Prevalence III-40
FDA Approval III-40
Strategic Corporate Developments III-40
Select Players III-42
BioCancell Therapeutics, Inc. (Israel) III-42
Bioniche Life Sciences, Inc. (Canada) III-42
China Medical Technologies Inc. (China) III-43
Lorus Therapeutics, Inc. (Canada) III-43
PharmaGap, Inc. (Canada) III-43
Viventia Biotechnologies, Inc. (Canada) III-43
B.Market Analytics III-44
Table 41: Rest of World Recent Past, Current and Future
Analysis for Bladder Cancer Therapeutics - Annual Revenues
in US$ Million for the Years 2007 through 2015 (includes
corresponding Graph/Chart) III-44
Table 42: Rest of World Historic Review for Bladder Cancer
Therapeutics - Annual Revenues in US$ Million for the Years
2001 through 2006 (includes corresponding Graph/Chart) III-45
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 62 (including Divisions/Subsidiaries - 67)
Region/Country Players
The United States 28
Canada 6
Japan 8
Europe 21
France 3
Germany 4
The United Kingdom 4
Spain 1
Rest of Europe 9
Asia-Pacific (Excluding Japan) 2
Middle-East 2
To order this report:
Drug and Medication Industry: Global Bladder Cancer Therapeutics Industry
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Contact Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
did anyone call sppi investor relations and ask when rituximab studies will commence or have they already begun test trials
hey folks anyone read this today February 04, 2011 10:00 AM Eastern Time
Research and Markets: Competitor Analysis: G-CSF and GM-CSF 2011
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/44f15d/competitor_analysi) has announced the addition of the "Competitor Analysis: G-CSF and GM-CSF" report to their offering.
The present Competitive Intelligence Report about G-CSF & GM-CSF products in the pipeline and off-patent products provides a competitor evaluation in the field of G-CSF & GM-CSF branded products in regulated markets and products in non-regulated markets, biosimilars (biogenerics, follow-on biologics) and next generation, longer acting products or new uses of G-CSF as of January 2011. Purchase of the downloadable PDF report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently marketed branded and non-branded G-CSF and GM-CSF products in regulated and non-regulated markets for treatment of chemotherapy-induced neutropenia. The report includes the market size of branded G-CSF products in 2009. It lists the most advanced biosimilars of G-CSF and pegylated G-CSF and of GM-CSF. It describes the companies with G-CSF and GM-CSF products and of pegylated versions in non-regulated markets. In addition, the report lists company-specific R&D pipelines of G-CSF/GM-CSF products and projects. Competitor projects are listed in a tabular format providing Information on:
* Drug Codes,
* Target / Mechanism of Action,
* Class of Compound,
* Company,
* Territory,
* Indication,
* R&D Stage and
* additional comments with a hyperlink leading to the source of information.
Key Topics Covered:
* 1st Generation branded G-CSF products in regulated markets
* Biosimilar 1st generation G-CSF products in regulated markets
* Next generation G-CSF products and uses in regulated markets
* Biosimilar next generation G-CSF products and uses in regulated markets
* 1st generation G-CSF products in non-regulated markets
* Next generation G-CSF products in non-regulated markets
* 1st and next generation GM-CSF products in regulated markets
* 1st and next generation GM-CSF products in non-regulated markets
* About La Merie
48 Companies Mentioned, Some Include:
Corporate G-CSF & GM-CSF R&D Pipelines
* Acorn Biomedical
* Amgen
* Apricus Biosciences
* Beijing SL
* Pharmaceutical Co
* Bolder BioTechnology
* Cangene
* Dong-A Pharmaceutical
* Fuji Pharma
* Genzyme
* Green Cross
* Hospira
* Intas Biopharmaceuticals
* Kyowa Hakko Kirin Pharma
* NCPC GeneTech Biotechnology Development
* Octapharma
* Phage Pharmaceuticals
* PharmaEssentia
* Recoly
* Reliance GeneMedix
* Reliance Life Sciences
* Serum Institute of India
* Shandong GeneLeuk Biopharma
* USV Ltd.
* Xiamen Amoytop Biotech
* Zenotech Laboratories
* Zydus Cadila
this stock is on fire
thanks olie,and thanks to the posts that keep us informed g/l everyone
if anyone has spoken to the company can you please share with the board..tia..shareholders really need a solid update
dude read your 8k ...
Section 3 – Securities and Trading Markets
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
We filed a Current Report on Form 8-K on December 28, 2009 to disclose the December 23, 2009 notice we received from NYSE Amex stating we were not in compliance with Section 1003(a)(iv) of the NYSE Amex LLC Company Guide (the “Company Guide”). As a result, we became subject to the procedures and requirements of Section 1009 of the Company Guide, pursuant to which were given the opportunity to submit a plan of compliance. The Amex approved the plan we submitted and gave us until June 23, 2010 to regain compliance. Since June, we have had additional conversations with Amex pursuant to which they granted us an extension until January 8, 2011 to submit an update to our plan. We submitted an update on January 14, 2011. On January 25, 2011, the Amex sent us a delisting notice stating their determination and belief that we did not make progress consistent with the plan and remain non-compliant with Sections 1003(a)(i), 1003(a)(ii), 1003(a)(iii), 1003(a)(iv) and 704 of the Amex Company Guide, and therefore, our securities are subject to immediate delisting proceedings.
Pursuant to our rights under theCompany Guide, we plan to appeal this determination and request a hearing before a Listing Qualifications Panel to explain our position that we should not be delisted and should remain a listed company on the Amex.
Pursuant to Section 1203(c) of the Amex Company Guide, our securities shall remain listed until the Amex determines that it is in the public’s best interest to suspend the trading of our securities or until the Panel makes its decision after the hearing.
it's my experience in offerings that this is typical the pps at 20% discount considering that you have a larger aggregated share count and or convertible debt this is jmho but again why own this stock when the company has nothing to offer shareholders other than more debt and facing a delisting notice..next they will convince me a reverse split is good for the company in order to satisfy???just askin
furthermore i see no interest to buy and own this stock when they have nothing to satisfy shareholders other than a promise...one thing we all know they are heading toward a delisting..please tell me why to buy and own here
i agree not looking good the pps should be cut atleast 20% from offering ,then whats to say no reverse split or the "placement"dumps shares into open market
will they dilute the shares more?
someone buy this and share Recent Study: Viropro Inc. (VPRO) - Financial and Strategic Analysis Review
Print article Print article
Refer this article Refer to a friend
2011-02-03 06:20:46 - Recently published research from GlobalData, "Viropro Inc. (VPRO) - Financial and Strategic Analysis Review", is now available at Fast Market Research
Viropro Inc. (VPRO) - Financial and Strategic Analysis Review
Summary
ViroNovative BV (ViroNovative) is a pharmaceutical company engaged in providing a complete solution to human Metapneumovirus (hMPV), a virus discovered at the department of virology in 2001. It is involved in developing diagnostics, antivirals and vaccines for the detection, prevention and treatment of hMPV infection. The company is a spin out formed
under the new active incubator policy of Erasmus University Rotterdam. ViroNovative is an active member of Viroventures, where it is in collaboration with Viroscope and ViroClinics to share the resources and expertise to fight against infectious diseases.
Viropro Inc. Key Recent Developments
Apr 14, 2010: Viropro Acquires Biologics Process Development From Intas Biopharmaceuticals
This comprehensive SWOT profile of Viropro Inc. provides you an in-depth strategic analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
This company report forms part of GlobalData's 'Profile on Demand' service, covering over 50,000 of the world's leading companies. Once purchased, GlobalData's highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Viropro Inc., including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).
The profile contains critical company information including*,
* Business description - A detailed description of the company's operations and business divisions.
* Corporate strategy - Analyst's summarization of the company's business strategy.
* SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
* Company history - Progression of key events associated with the company.
* Major products and services - A list of major products, services and brands of the company.
* Key competitors - A list of key competitors to the company.
* Key employees - A list of the key executives of the company.
* Executive biographies - A brief summary of the executives' employment history.
* Key operational heads - A list of personnel heading key departments/functions.
* Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
* Key manufacturing facilities - A list of key manufacturing facilities of the company.
* Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
* Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note*: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include,
You get detailed information about the company and its operations to identify potential customers and suppliers.
* The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
* The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
* Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
* Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
* Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
For more information or to purchase this report, go to:
- www.fastmr.com/prod/112613_viropro_inc_vpro_financial_and_strate ..
About GlobalData
GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.
im all for it..the o/s will still be low and secure the pipeline{our own best interest}so i don't see this as a problem in anyway..these drugs may become blockbusters..
thinking of adding myself right now
they just might need the funding to ensure the developments for their pipeline drugs..still a low float with under 12 mil o/s..no brainer
buy/sell i don't care give me volume
more on this?????Viropro Wishes to Update Investors and the Investment Community on Its Operations
Viropro (USOTC:VPRO)
Historical Stock Chart
1 Month : January 2011 to February 2011
Click Here for more Viropro Charts.
Viropro (PK: VPRO) wishes to update investors and the investment community on its operations. Recent headlines on the Company have attracted considerable attention and management wishes to outline the following:
* Financial Statements of the Company have been audited for the period ending December 31, 2009 and quarterlies have been reviewed until March 31, 2010.
* Company intends to file updated unaudited financial statements on the Pink Sheet; those statements will be consolidated and will include those of its 100% owned subsidiaries Biologics Process Development Inc. of San Diego and Viropro International of Montreal, QC. Filing is scheduled for the end of February.
* Once the financials are filed, Company will request that auditing be conducted which in turn will allow Company to solicit better listing opportunities.
* A 25% reduction in the number of fully diluted outstanding shares has just been operated. A reserve of 108,015,823 shares for the conversion of a debenture was cancelled as said debenture was bought back.
* Company is requesting to be included in the FAST program whereby all stock transactions would be treated electronically.
* Company is currently updating its website for further references.
Viropro’s business plan calls for a one stop shop in Biotechnology Contractual Development and Manufacturing Services and to do so, acquisitions will be necessary. Said business plan will not be made available to the public as potential acquisitions are clearly stated. Viropro’s entire management is keen on implementing said plan and is highly motivated towards reaching that goal.
anyone email investor relations lately and get an update?
thanks i expect a cover soon to fill the gap
Upcoming Events
Thirteenth Annual BIO CEO & Investor Conference
Tuesday, February 15, 2011, 9:00 a.m. Eastern
Waldorf-Astoria, New York City
bagholders galore...TIIIIIMMMMMMMBBBBBBEEEEEEEEERRRRRRRR
tia anything could help at this point
i'll wait for 29 cents on pinks this one could delist at any moment
please let me know when you think this has hit bottom cause this has been down everyday but 1 for the past 13 sessions
can this slug trade any slower?
all i hear is delist....imho?
what time today does rpc delist?
you would think at 3.5 mm's would let her go... no volume who cares?
im ready to put that 4 cent buy order in
now reverse split delist
junk grey sheet SCAM BEWARE
here is a great read 20 mins ago http://www.dnaindia.com/money/report_lupin-global-ride-hinges-on-the-power-of-five_1501122
this junk stock will delist and you will lose all your money ..buyer beware..this will never be amex compliant so take your losses and run..i owned this and sold i won't be buying back either
scum trashed this stock to where it is now this is gross....i'll wait it out on news this is a real company ..so let the scum continue..i ;ll buy on the dips and looking for the 03 2.8's then we can move higher but i'll take all the shares before that
this volume is disgusting